<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459877</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1542</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101542</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9-16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7-35.1%) (<i>p</i> &lt; 0.001). The 30-day mortality rates were comparable between both groups (<i>p</i> = 0.982). Analysis of SARS-CoV-2 PCR negativity showed no difference between the two treatment groups (95.2% [93.0-96.9%] and 93.5% [89.1-96.6%] until day 30, <i>p</i> = 0.851 for Bamlanivimab/Etesevimab and Casirivimab/Imdevimab, respectively). Among persistently positive samples with available sequencing results (<i>n</i> = 43), Spike protein changes occurred only in Bamlanivimab/Etesevimab (42.9%) vs. Casirivimab/Imdevimab (0.0%) groups. Q493R (25.0%) and E484K (12.5%) were the most common mutations selected by Bamlanivimab/Etesevimab in follow-up samples. Other factors (immunodepression, comorbidities, and age) did not appear to be associated with the occurrence of Spike protein mutations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE<sup>®</sup>) in comparison with Bamlanivimab/Etesevimab treatment, but with the emergence of Spike mutations only in the Bamlanivimab/Etesevimab group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zafilaza</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0000-2071-9395</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellet</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Département de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truffot</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7991-1733</Identifier><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Commisariat à l'Energie Atomique, Institut de Recherche Interdisciplinaire de Grenoble Institut de Biologie Structurale, University Grenoble Alpes, 38000 Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foulongne</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3741-754X</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire Montpellier, 34090 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onambele</LastName><ForeName>Manuela Mireille</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Unité Mixte de Recherche 1137 Infection Antimicrobials Modelling Evolution, Institut Nationale de la Santé et de la Recherche Médicale, Université Paris Cité, Assistance Publique -Hôpitaux de Paris Nord Hôpital Bichat-Claude-Bernard, 75018 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmona</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Unité 941, Institut Nationale de la Santé et de la Recherche Médicale, Hôpital Saint-Louis, Université de Paris, Assistance Publique-Hôpitaux de Paris, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Camille</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8637-6695</Identifier><AffiliationInfo><Affiliation>Laboratoire de virologie, Centre Hospitalier Universitaire Toulouse Purpan, Institut Nationale de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1291, 31300 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Périllaud-Dubois</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4711-5852</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpital Universitaire Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirand</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9638-2415</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire de Clermont-Ferrand, 63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André-Garnier</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alidjinou</LastName><ForeName>Enagnon Kazali</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire Lille, Université de Lille, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brichler</LastName><ForeName>Ségolène</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpital Avicennes, Assistance Publique-Hôpitaux de Paris, 93000 Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenaux</LastName><ForeName>Honorine</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7200-5976</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire Paul Brousse, Assistance Publique-Hôpitaux de Paris, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouvier-Alias</LastName><ForeName>Magali</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1590-5980</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartard</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5942-2345</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Régional et Universitaire de Nancy Brabois, Laboratoire de Chimie Physique et Microbiologie pour les matériaux et l'Environnement, Centre National de la Recherche Scientifique, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorival</LastName><ForeName>Céline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Département de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcelin</LastName><ForeName>Anne-Geneviève</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-4808-8999</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefic</LastName><ForeName>Karl</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9686-9194</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier et Régional Universitaire de Tours, Unité 1259, Institut Nationale de la Santé et de la Recherche Médicale, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soulie</LastName><ForeName>Cathia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0008-2032-4148</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711751">casirivimab and imdevimab drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7Q9NLF11I</RegistryNumber><NameOfSubstance UI="C000711968">etesevimab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717627">bamlanivimab and etesevimab drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>45I6OFJ8QH</RegistryNumber><NameOfSubstance UI="C000711749">bamlanivimab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J0FI6WE1QN</RegistryNumber><NameOfSubstance UI="C000711487">casirivimab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune escape mutation</Keyword><Keyword MajorTopicYN="N">monoclonal antibody therapy</Keyword><Keyword MajorTopicYN="N">spike gene</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests with the current work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459877</ArticleId><ArticleId IdType="pmc">PMC11512400</ArticleId><ArticleId IdType="doi">10.3390/v16101542</ArticleId><ArticleId IdType="pii">v16101542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Focosi D., McConnell S., Casadevall A., Cappello E., Valdiserra G., Tuccori M. Monoclonal Antibody Therapies against SARS-CoV-2. Lancet Infect. Dis. 2022;22:e311–e326. doi: 10.1016/S1473-3099(22)00311-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00311-5</ArticleId><ArticleId IdType="pmc">PMC9255948</ArticleId><ArticleId IdType="pubmed">35803289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M., Nirula A., Azizad M., Mocherla B., Gottlieb R.L., Chen P., Hebert C., Perry R., Boscia J., Heller B., et al. Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19. N. Engl. J. Med. 2021;385:1382–1392. doi: 10.1056/NEJMoa2102685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102685</ArticleId><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M., Azizad M., Mocherla B., Gottlieb R.L., Chen P., Hebert C., Perry R., Boscia J., Heller B., Morris J., et al. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clin. Infect. Dis. 2022;75:e440–e449. doi: 10.1093/cid/ciab912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab912</ArticleId><ArticleId IdType="pmc">PMC9402688</ArticleId><ArticleId IdType="pubmed">34718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O., Abani O., Abbas A., Abbas A., Abbas F., Abbas F., Abbas M., Abbas M., Abbasi S., Abbasi S., et al. Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. Lancet. 2022;399:665–676. doi: 10.1016/S0140-6736(22)00163-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00163-5</ArticleId><ArticleId IdType="pmc">PMC8830904</ArticleId><ArticleId IdType="pubmed">35151397</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich D.M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Xiao J., Hooper A.T., Hamilton J.D., Musser B.J., et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with COVID-19. N. Engl. J. Med. 2021;385:e81. doi: 10.1056/NEJMoa2108163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta D., Naiyer S., Mansuri S., Soni N., Singh V., Bhat K.H., Singh N., Arora G., Mansuri M.S. COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2. Diagnostics. 2022;12:1503. doi: 10.3390/diagnostics12061503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12061503</ArticleId><ArticleId IdType="pmc">PMC9221722</ArticleId><ArticleId IdType="pubmed">35741313</ArticleId></ArticleIdList></Reference><Reference><Citation>Leducq V., Zafilaza K., Fauchois A., Ghidaoui E., Sayon S., Dorival C., Meledje M.-L., Lusivika-Nzinga C., Yordanov Y., Martin-Blondel G., et al. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies. J. Infect. Dis. 2023;229:1341–1351. doi: 10.1093/infdis/jiad523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad523</ArticleId><ArticleId IdType="pubmed">37996072</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurini E., Marson D., Aulic S., Fermeglia A., Pricl S. Molecular Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies. Sci. Rep. 2021;11:20274. doi: 10.1038/s41598-021-99827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99827-3</ArticleId><ArticleId IdType="pmc">PMC8511038</ArticleId><ArticleId IdType="pubmed">34642465</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiffer-Smadja N., Bridier-Nahmias A., Ferré V.M., Charpentier C., Garé M., Rioux C., Allemand A., Lavallée P., Ghosn J., Kramer L., et al. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021;13:1642. doi: 10.3390/v13081642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081642</ArticleId><ArticleId IdType="pmc">PMC8402761</ArticleId><ArticleId IdType="pubmed">34452507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr B., Niemann D., Verheyen J. Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient. Clin. Infect. Dis. 2021;73:2144–2145. doi: 10.1093/cid/ciab392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab392</ArticleId><ArticleId IdType="pubmed">34009286</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Novazzi F., Genoni A., Dentali F., Gasperina D.D., Baj A., Maggi F. Emergence of SARS-CoV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. Emerg. Infect. Dis. 2021;27:2728–2731. doi: 10.3201/eid2710.211538.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2710.211538</ArticleId><ArticleId IdType="pmc">PMC8462334</ArticleId><ArticleId IdType="pubmed">34314668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen B., Luebke N., Feldt T., Keitel V., Brandenburger T., Kindgen-Milles D., Lutterbeck M., Freise N.F., Schoeler D., Haas R., et al. Emergence of the E484K Mutation in SARS-CoV-2-Infected Immunocompromised Patients Treated with Bamlanivimab in Germany. Lancet Reg. Health Eur. 2021;8:100164. doi: 10.1016/j.lanepe.2021.100164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100164</ArticleId><ArticleId IdType="pmc">PMC8278033</ArticleId><ArticleId IdType="pubmed">34278371</ArticleId></ArticleIdList></Reference><Reference><Citation>Guigon A., Faure E., Lemaire C., Chopin M.-C., Tinez C., Assaf A., Lazrek M., Hober D., Bocket L., Engelmann I., et al. Emergence of Q493R Mutation in SARS-CoV-2 Spike Protein during Bamlanivimab/Etesevimab Treatment and Resistance to Viral Clearance. J. Infect. 2022;84:248–288. doi: 10.1016/j.jinf.2021.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.08.033</ArticleId><ArticleId IdType="pmc">PMC8381628</ArticleId><ArticleId IdType="pubmed">34437928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Gaudreault N.N., Meekins D.A., Perera K.D., Bold D., Trujillo J.D., Morozov I., McDowell C.D., Chang K.-O., Richt J.A. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. Microbiol. Spectr. 2022;10:e01789-21. doi: 10.1128/spectrum.01789-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01789-21</ArticleId><ArticleId IdType="pmc">PMC9241865</ArticleId><ArticleId IdType="pubmed">35638818</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Nie J., Wu J., Zhang L., Ding R., Wang H., Zhang Y., Li T., Liu S., Zhang M., et al. SARS-CoV-2 501Y.V2 Variants Lack Higher Infectivity but Do Have Immune Escape. Cell. 2021;184:2362–2371.e9. doi: 10.1016/j.cell.2021.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.042</ArticleId><ArticleId IdType="pmc">PMC7901273</ArticleId><ArticleId IdType="pubmed">33735608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., Ye C., Rathnasinghe R., Stadlbauer D., Personalized Virology Initiative study group. Krammer F., Simon V., Martinez-Sobrido L., García-Sastre A., Schotsaert M. SARS-CoV-2 Spike E484K Mutation Reduces Antibody Neutralisation. Lancet Microbe. 2021;2:e283–e284. doi: 10.1016/S2666-5247(21)00068-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00068-9</ArticleId><ArticleId IdType="pmc">PMC8026167</ArticleId><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Nirula A., Heller B., Gottlieb R.L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19. N. Engl. J. Med. 2021;384:229–237. doi: 10.1056/NEJMoa2029849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2029849</ArticleId><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasundaram P., Morgan-Joseph T. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Etesevimab.</Citation><ArticleIdList><ArticleId IdType="pubmed">34283469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mader A.-L., Tydykov L., Glück V., Bertok M., Weidlich T., Gottwald C., Stefl A., Vogel M., Plentz A., Köstler J., et al. Omicron’s Binding to Sotrovimab, Casirivimab, Imdevimab, CR3022, and Sera from Previously Infected or Vaccinated Individuals. iScience. 2022;25:104076. doi: 10.1016/j.isci.2022.104076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104076</ArticleId><ArticleId IdType="pmc">PMC8920075</ArticleId><ArticleId IdType="pubmed">35309727</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich D.M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Musser B.J., Soo Y., Rofail D., Im J., et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. N. Engl. J. Med. 2021;384:238–251. doi: 10.1056/NEJMoa2035002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jary A., Marot S., Faycal A., Leon S., Sayon S., Zafilaza K., Ghidaoui E., Quoc S.N., Nemlaghi S., Choquet S., et al. Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies. Viruses. 2022;14:226. doi: 10.3390/v14020226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020226</ArticleId><ArticleId IdType="pmc">PMC8877338</ArticleId><ArticleId IdType="pubmed">35215820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Konnova A., Smet M., Berkell M., Savoldi A., Morra M., Averbeke V.V., Winter F.H.R.D., Peserico D., Danese E., et al. Host Immunological Responses Facilitate Development of SARS-CoV-2 Mutations in Patients Receiving Monoclonal Antibody Treatments. J. Clin. Investig. 2023;133:e166032. doi: 10.1172/JCI166032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI166032</ArticleId><ArticleId IdType="pmc">PMC10014108</ArticleId><ArticleId IdType="pubmed">36727404</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., McConnell S., Sullivan D.J., Casadevall A. Analysis of SARS-CoV-2 Mutations Associated with Resistance to Therapeutic Monoclonal Antibodies That Emerge after Treatment. Drug Resist. Updates. 2023;71:100991. doi: 10.1016/j.drup.2023.100991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2023.100991</ArticleId><ArticleId IdType="pubmed">37572569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T., Vrignaud L.-L., Porrot F., Staropoli I., Planas D., Guivel-Benhassine F., Puech J., Prot M., Munier S., Bolland W.H., et al. Sotrovimab Therapy Elicits Antiviral Activities against Omicron BQ.1.1 and XBB.1.5 in Sera of Immunocompromised Patients. Med. 2023;4:664–667. doi: 10.1016/j.medj.2023.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.07.007</ArticleId><ArticleId IdType="pmc">PMC11232389</ArticleId><ArticleId IdType="pubmed">37837962</ArticleId></ArticleIdList></Reference><Reference><Citation>Traitement par Paxlovid® des patients à risque de Forme Grave de COVID-19.  [(accessed on 9 November 2022)].  Available online:  https://www.has-sante.fr/jcms/p_3310993/fr/traitement-par-paxlovid-des-patients-a-risque-de-forme-grave-de-covid-19.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>